Search results
CVS Caremark’s Policy Shift On Humira Biosimilars May Not Be What The Doctor Ordered
Forbes· 4 days agoAs of March, the blockbuster autoimmune drug Humira (adalimumab) still held 96% of the market share...
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks via Yahoo Finance· 3 days agoKymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the...
How to treat foot calluses, according to experts
NBC Universal via AOL· 4 days agoThe full body cream is technically formulated for psoriasis and has salicylic acid and lactic acid to help gently exfoliate. She particularly likes that...
Is Algae Oil the New Fish Oil?
Men's Health via Yahoo News· 6 days agoAlgae oil is all the rage right now as a vegetarian replace to fish oil. Dietitians explain its health benefits, uses, and risks associated with using...
Amgen (NASDAQ:AMGN) Price Target Cut to $328.00
ETF DAILY NEWS· 1 day agoAmgen (NASDAQ:AMGN – Get Free Report) had its price target reduced by Royal Bank of Canada from $332.00 to $328.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently ...
Digital Health Sector Slowed Down in 2023
Medscape· 3 days agoAlthough the average amount raised in European funding rounds decreased, the number of investors increased by nearly one quarter.
Change Eligibility Rules for More Diverse Clinical Trials?
Medscape· 3 days agoExpanding eligibility criteria is a strategy for improving the inclusion of traditionally...
Amgen (NASDAQ:AMGN) Rating Increased to Outperform at William Blair
ETF DAILY NEWS· 2 days agoAmgen (NASDAQ:AMGN – Get Free Report) was upgraded by William Blair from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Friday, MarketBeat ...
AbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 6 days agoAbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call Transcript April 26, 2024 AbbVie Inc. beats earnings...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit...
Morningstar· 7 days agoThe Law Offices of Frank R. Cruz reminds investors of the upcoming April 30, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Ventyx ...
